Please assess the completion status of the following clinical trial:

Trial Title: Genetic Basis for Variation in the Renal Elimination of Metformin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects have previously participated in the Study Of Pharmacogenetics In Ethnically Diverse Populations (SOPHIE) study.~* 18-40 years old~* Possess a pre-specified genotype for OCT2~Exclusion Criteria:~* Taking any regular medications other than vitamins.~* Individuals with anemia (hemoglobin \< 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL)~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- OCT2-variant Group (Type: EXPERIMENTAL): Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
- OCT2-reference Group (Type: EXPERIMENTAL): Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).